Exploring the Potential of Monoclonal Antibody L2A5

Funding Information: This work received financial support from PT national funds (FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior) through CI-IPOP project UIDP/00776/2020, FCT project BioFaec (http://doi.org/10.54499/2022.09051.PTDC, accessed on 1 March 2024) and ONCOSCREEN (grant agreement No. 101097036) and the funding UIDP/04378/2020 and UIDB/04378/2020 to UCIBIO research unit and LA/P/0140/2020 to the i4HB Associate Laboratory. P.A.V. also thanks project InnoGlyco (ref: 2022.04607.PTDC). This work was cofounded by the project “The Porto Comprehensive Cancer Centre Raquel Seruca” with the reference NORTE-01-0145-FEDER-0726678—Consorcio PORTO. CCC—Porto.Comprehensive Cancer Centre Raquel Seruca, supported by Norte Portugal Regional Operational Programme (NORTE 2020) under the PORTUGAL 2020 Partnership Agreement through the European Regional Development Fund (ERDF), Portugal. FCT is co-financed by the European Social Fund (ESF) under the Human Potential Operation Programme (POPH) from the National Strategic Reference Framework (NSRF). The authors also thank the financial support of the Portuguese Oncology Institute of Porto— Research Centre (CI-IPOP-77–2017-2024). The authors also wish to acknowledge funding from FCT for PhD Grants BD/04511/2024 (ME) and UI/BD/154820/2023 (DARS). JS would like to acknowl edge an Advanced Investigation Grant from the Portuguese League Against Cancer. RC would like to acknowledge 2022.09051.PTDC + PI177-CI-IPOP-01-2023-HORIZON-ONCOSCREEN grant under the scopes of BioFaec and ONCOSCREEN. LL acknowledges the research position from FCT (DL 57/2016/CP1491/CT0002) and under the scope of ONCOSCREEN (PI177-CI-IPOP-01-2023- HORIZON-ONCOSCREEN_ASSRES). Publisher Copyright: © 2025 by the authors.